Monthly
US$200
Billed every month
Ceftazidime And Avibactam Sodium For Injection(注射用头孢他啶阿维巴坦钠)
Companies, stages and changes, with each record available on this page.
Last 90 days: Supplement delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders24View records ↓
Under-review filings12View records ↓
This year’s generic filers4View records ↓
NHSA approval numbers25View records ↓
API companies with A status0View records ↓
Chemical-drug catalogue
Loaded records: 24 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 23 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 海南广升誉制药有限公司 | 海南广升誉制药有限公司 | 国药准字H20265786 | 2026/09/02 | 1.25g（C22H22N6O7S2 1.0g与C7H11N3O6S 0.25g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南广升誉制药有限公司 | 海南广升誉制药有限公司 | 国药准字H20265787 | 2026/09/02 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福安药业集团庆余堂制药有限公司 | 福安药业集团庆余堂制药有限公司 | 国药准字H20265419 | 2026/07/28 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南合瑞制药股份有限公司 | 海南合瑞制药股份有限公司 | 国药准字H20265205 | 2026/07/14 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 哈药集团制药总厂 | 哈药集团制药总厂 | 国药准字H20264794 | 2026/06/17 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南柏齐鹤药物研发有限公司 | 福建省福抗药业股份有限公司 | 国药准字H20264223 | 2026/05/07 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湘北威尔曼制药股份有限公司 | 湘北威尔曼制药股份有限公司 | 国药准字H20263191 | 2026/01/27 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北民康药业集团有限公司 | 上海欣峰制药有限公司 | 国药准字H20256204 | 2025/12/09 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华北制药河北华民药业有限责任公司 | 华北制药河北华民药业有限责任公司 | 国药准字H20254420 | 2025/06/03 | 2.5g（C22H22N6O7S2 2.0g与 C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川制药制剂有限公司 | 四川制药制剂有限公司 | 国药准字H20254290 | 2025/05/27 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都倍特药业股份有限公司 | 成都倍特药业股份有限公司 | 国药准字H20253763 | 2025/04/01 | 2.5g（C22H22N6O7S2 2.0g 与 C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 正大天晴药业集团股份有限公司 | 连云港润众制药有限公司 | 国药准字H20253156 | 2025/01/14 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 瑞阳制药股份有限公司 | 瑞阳制药股份有限公司 | 国药准字H20253047 | 2025/01/02 | 2.5g（C22H22N6O7S2 2.0g 与 C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京恩泰医药科技有限公司 | 海南合瑞制药股份有限公司 | 国药准字H20249768 | 2024/12/25 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州二叶制药有限公司 | 齐鲁安替制药有限公司 | 国药准字H20249702 | 2024/12/06 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南海灵化学制药有限公司 | 海口市制药厂有限公司 | 国药准字H20249571 | 2024/12/01 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 沈阳三九药业有限公司 | 沈阳三九药业有限公司 | 国药准字H20244625 | 2024/08/05 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东百诺医药股份有限公司 | 海口市制药厂有限公司 | 国药准字H20243954 | 2024/06/04 | 2.5g（C<sub>22</sub>H<sub>22</sub>N<sub>6</sub>O<sub>7</sub>S<sub>2</sub> 2.0g与C<sub>7</sub>H<sub>11</sub>N<sub>3</sub>O<sub>6</sub>S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江惠迪森药业有限公司 | 浙江惠迪森药业有限公司 | 国药准字H20243532 | 2024/04/17 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海欣峰制药有限公司 | 上海欣峰制药有限公司 | 国药准字H20243177 | 2024/02/06 | 2.5g（C22H22N6O7S2 2.0g 与 C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京力博维制药有限公司 | 南京优科制药有限公司 | 国药准字H20234289 | 2023/10/12 | 2.5g(C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广西科伦制药有限公司 | 广西科伦制药有限公司 | 国药准字H20234291 | 2023/10/12 | 2.5g(C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药有限公司 | 齐鲁制药有限公司 | 国药准字H20213758 | 2021/09/30 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Pfizer Ireland Pharmaceuticals | ACS Dobfar S.p.A. | H20190038 | 2019/05/21 | 2.5g(含头孢他啶2g和阿维巴坦0.5g ) | Imported originator drug (进口原研药品) | CDE |
| Pfizer Ireland Pharmaceuticals | GlaxoSmithKline Manufacturing S.p.A | H20190038 | 2019/05/21 | 2.5g(C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g ) | Imported originator drug (进口原研药品) | CDE |
| 安徽威尔曼制药有限公司 | 安徽威尔曼制药有限公司 | 国药准字H20255448 | 2025/09/09 | 2.5g（C22H22N6O7S2 2.0g与C7H11N3O6S 0.5g） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 25 distinct approval numbers and 24 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 正大天晴药业集团股份有限公司 | 国药准字H20253156 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010101523 | NHSA |
| 山东二叶制药有限公司 | 国药准字H20249702 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010101651 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20265419 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g 与 C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010101877 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20253763 | 2.5g(C₂₂H₂₂N₆O₇S₂2.0g与C₇H₁₁N₃O₆S0.5g) | Category B (乙) | XJ01DDT188B001010102013 | NHSA |
| 四川制药制剂有限公司 | 国药准字H20254290 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010102297 | NHSA |
| 华北制药河北华民药业有限责任公司 | 国药准字H20254420 | 2.5g(C22H22N6O7S2 2.0g 与 C7H11N3O6S 0.5g) | Category B (乙) | XJ01DDT188B001010102693 | NHSA |
| 哈药集团制药总厂 | 国药准字H20264794 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010103712 | NHSA |
| 齐鲁制药有限公司 | 国药准字H20213758 | 2.5g(C₂₂H₂₂N₆O₇S₂2.0g与C₇H₁₁N₃O₆S0.5g) | Category B (乙) | XJ01DDT188B001010104021 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20253047 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g 与 C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010104152 | NHSA |
| 安徽威尔曼制药有限公司 | 国药准字H20255448 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010104355 | NHSA |
| 浙江惠迪森药业有限公司 | 国药准字H20243532 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010104651 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20263191 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010105025 | NHSA |
| 广西科伦制药有限公司 | 国药准字H20234291 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010105194 | NHSA |
| 海南海灵化学制药有限公司 | 国药准字H20249571 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010105775 | NHSA |
| 海南合瑞制药股份有限公司 | 国药准字H20265205 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010105815 | NHSA |
| 沈阳三九药业有限公司 | 国药准字H20244625 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010109626 | NHSA |
| Pfizer Ireland Pharmaceuticals Unlimited Company | 国药准字HJ20190038 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g 与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010178719 | NHSA |
| 上海欣峰制药有限公司 | 国药准字H20243177 | 2.5g(C22H22N6O7S2 2.0g与C7H11N3O6S0.5g) | Category B (乙) | XJ01DDT188B001010180532 | NHSA |
| 南京力博维制药有限公司 | 国药准字H20234289 | 2.5g(C22H22N6O7S2 2.0g与C7H11N3O6S0.5g) | Category B (乙) | XJ01DDT188B001010180542 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20265786 | 1.25g(C₂₂H₂₂N₆O₇S₂ 1.0g与C₇H₁₁N₃O₆S 0.25g) | Category B (乙) | XJ01DDT188B001010181251 | NHSA |
| 国药集团致君(深圳)制药有限公司 | 国药准字H20243954 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010183011 | NHSA |
| 南京恩泰医药科技有限公司 | 国药准字H20249768 | 2.5g(C22H22N6O7S2 2.0g与C7H11N3O6S0.5g) | Category B (乙) | XJ01DDT188B001010183607 | NHSA |
| 海南丰恺思制药有限公司 | 国药准字H20264223 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010184017 | NHSA |
| 湖北民康药业集团有限公司 | 国药准字H20256204 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010184564 | NHSA |
| 山东二叶制药有限公司 | 国药准字H20249702 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010201651 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20265419 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g 与 C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010201877 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20253763 | 2.5g(C₂₂H₂₂N₆O₇S₂2.0g与C₇H₁₁N₃O₆S0.5g) | Category B (乙) | XJ01DDT188B001010202013 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20253047 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g 与 C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010204152 | NHSA |
| 浙江惠迪森药业有限公司 | 国药准字H20243532 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010204651 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20263191 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010205025 | NHSA |
| 广西科伦制药有限公司 | 国药准字H20234291 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010205194 | NHSA |
| 海南海灵化学制药有限公司 | 国药准字H20249571 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010205775 | NHSA |
| 海南合瑞制药股份有限公司 | 国药准字H20265205 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010205815 | NHSA |
| Pfizer Ireland Pharmaceuticals Unlimited Company | 国药准字HJ20190038 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g 与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010278719 | NHSA |
| 上海欣峰制药有限公司 | 国药准字H20243177 | 2.5g(C22H22N6O7S2 2.0g与C7H11N3O6S0.5g) | Category B (乙) | XJ01DDT188B001010280532 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20265786 | 1.25g(C₂₂H₂₂N₆O₇S₂ 1.0g与C₇H₁₁N₃O₆S 0.25g) | Category B (乙) | XJ01DDT188B001010281251 | NHSA |
| 南京恩泰医药科技有限公司 | 国药准字H20249768 | 2.5g(C22H22N6O7S2 2.0g与C7H11N3O6S0.5g) | Category B (乙) | XJ01DDT188B001010283607 | NHSA |
| 湖北民康药业集团有限公司 | 国药准字H20256204 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010284564 | NHSA |
| 湘北威尔曼制药股份有限公司 | 国药准字H20263191 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001010305025 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20265787 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001020181251 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20265787 | 2.5g(C₂₂H₂₂N₆O₇S₂ 2.0g与C₇H₁₁N₃O₆S 0.5g) | Category B (乙) | XJ01DDT188B001020281251 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 12 filings and 11 distinct first applicants.
Generic 11 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 湖北广济药业股份有限公司;山东鲁抗医药股份有限公司 | CYHS2601870 | Generic | 2026/08/03 | Not stated by source | CDE |
| 山东鲁抗医药股份有限公司 | CYHS2600796 | Generic | 2026/04/08 | Not stated by source | CDE |
| 山东鲁抗三叶制药有限公司 | CYHS2502079 | Generic | 2025/06/12 | Not stated by source | CDE |
| 南京恩泰医药科技有限公司;海南合瑞制药股份有限公司 | CYHB2600191 | Supplement | 2026/01/29 | Not stated by source | CDE |
| 苏州东瑞制药有限公司 | CYHS2601307 | Generic | 2026/06/04 | Not stated by source | CDE |
| 海南全星制药有限公司 | CYHS2600585 | Generic | 2026/02/28 | Not stated by source | CDE |
| 广东金城金素制药有限公司 | CYHS2504254 | Generic | 2025/12/11 | Not stated by source | CDE |
| 广东金城金素制药有限公司 | CYHS2504253 | Generic | 2025/12/11 | Not stated by source | CDE |
| 海口市制药厂有限公司 | CYHS2503296 | Generic | 2025/09/05 | Not stated by source | CDE |
| 浙江普洛巨泰药业有限公司 | CYHS2502899 | Generic | 2025/08/09 | Not stated by source | CDE |
| 山东致泰医药技术有限公司;海南合瑞制药股份有限公司 | CYHS2501260 | Generic | 2025/04/03 | Not stated by source | CDE |
| 海南葫芦娃药业集团股份有限公司 | CYHS2401725 | Generic | 2024/06/07 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 4 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 湖北广济药业股份有限公司;山东鲁抗医药股份有限公司 | CYHS2601870 | Generic | 2026/08/03 | Not stated by source | CDE |
| 山东鲁抗医药股份有限公司 | CYHS2600796 | Generic | 2026/04/08 | Not stated by source | CDE |
| 苏州东瑞制药有限公司 | CYHS2601307 | Generic | 2026/06/04 | Not stated by source | CDE |
| 海南全星制药有限公司 | CYHS2600585 | Generic | 2026/02/28 | Not stated by source | CDE |
API registrations
Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/16Supplement delivery
辉瑞投资有限公司
JYHB2500259
Fact date: 2026/10/16 · Publication date: 2026/10/19 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 40 ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Ceftazidime And Avibactam Sodium For Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy